^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Cutaneous Melanoma
    Drug:Opdualag (nivolumab/relatlimab-rmbw) (PD1 inhibitor, LAG-3 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    NCCN
    Published date:
    04/11/2022
    Excerpt:
    Melanoma: Cutaneous...First-Line Therapy; Preferred regimens: Nivolumab and relatlimab-rmbw combination therapy was added as an option...